Program

WEDNESDAY, November 1st  2017

08:45 // Registration, Coffee & Mingling

09:15 // Welcome by the Norwegian Cancer Society

              Elisabeth Authen Sethre

09:30-11:00 // SESSION 1 (Chair: Anders Bjartell, Lund University, Malmø, Sweden)

09:30 // Early risk prediction

              Monique J. Roobol, Erasmus Medical Centre, Rotterdam, The Netherlands.

10:00 // Risk prediction in prostate cancer patients

              Nicolas Mottet,  University Jean Monnet, Saint-Etienne, France & Jan Oldenburg, Akershus University Hospital, Norway.

11:00 // Break

11:30-13:15 // SESSION 2 (Chair: Tuomas Mirtti, University of Helsinki, Finland)

11:30 // Biomarkers: Definition, requirements, pitfalls

     Bart Kiemeney, Radboud University, Nijmegen, The Netherlands.

12:00 // Heterogeneity in Prostate Cancer

     G. Steven  Bova,  University of Tampere and Tampere University Hospital,  Finland.

12:30 // Developing clinically relevant biomarkers in prostate cancer

     Stephen Pennington, UCD Conway Institute of Biomolecular and Biomedical Science Research, Dublin, Ireland.

13:00 // Patient needs

              Daniel Ask, VP, Patient organisation for Prostate Cancer Patients Norway (PROFO).

13:15 // Lunch

14:15-15:45 // SESSION 3 (Chair: Antoinette Perry, UCD, Dublin, Ireland)

14:15 // Genetic variants linked to risk stratification

              William B. Isaacs, Johns Hopkins University School of Medicine.

14:45 // Methylation signatures in urine

              Antoinette Perry, UCD Conway Institute of Biomolecular and Biomedical Science Research, Dublin, Ireland.

15:15 // MRSI for clinical use - limitations and possibilities

              Arend Heerschap, Radboud University Nijmegen Medical Center, The Netherlands.